Overview: NGS Optic Atrophy Sequencing TestIntroduction: The NGS Optic Atrophy Sequencing Test sequences genes to diagnose optic atrophy, causing vision loss. Following 2023 AAO guidelines, it uses PCR for high specificity, supporting vision screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in molecular pathology for patients with suspected optic atrophy.
Other Names: Optic Atrophy Assay, OPA1 Gene Test.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: Optic atrophy sequencing began in the 2000s with optic neuropathy research. NGS methods improved in the 2010s, enhancing diagnostic precision.
Purpose: Sequences genes to diagnose optic atrophy, guides treatment, and evaluates patients with vision loss.
Test Parameters: 1. Optic Atrophy Genes
Pretest Condition: No fasting required. Collect whole blood, buccal swab, or saliva. Report history of vision loss, color vision defects, or optic atrophy symptoms.
Specimen: Whole Blood (EDTA, 2-5 mL), Buccal Swab (sterile swab, 1-2 swabs), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document vision loss, color vision defects, or family history of optic atrophy. Include current medications, especially vision-related treatments.
Consent: Written consent required, detailing the tests purpose, optic atrophy implications, and risks of sample collection.
Procedural Considerations: Uses next-generation sequencing to analyze optic atrophy genes (e.g., OPA1). Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for optic atrophy diagnosis.
Factors Affecting Result Accuracy: Low DNA yield or improper sample storage can affect results. Contamination may reduce specificity.
Clinical Significance: Identified mutations confirm optic atrophy, guiding supportive care or genetic counseling. Negative results may require mitochondrial DNA testing.
Specialist Consultation: Consult an ophthalmologist or geneticist for result interpretation and treatment planning.
Additional Supporting Tests: Visual field testing, optic nerve imaging, or ERG to confirm optic atrophy diagnosis.
Test Limitations: Not all optic atrophy cases are genetic; clinical correlation is needed. Sample quality affects sensitivity.
References: AAO Optic Atrophy Guidelines, 2023; Ophthalmology, Lenaers G, 2022.
